SurModics, a provider of drug delivery and surface modification technologies, has opened a new facility for manufacturing and development in Birmingham, Alabama.
The facility reportedly supports several recently announced partnerships, including one with Roche and Genentech, a wholly-owned member of the Roche Group, to develop and commercialize a sustained drug delivery formulation of Lucentis and other formulations for the treatment of ophthalmic diseases.
The facility also enhances SurModics's capabilities to support its customers and expand future growth, and allows the company to consolidate its other Birmingham operations into one location.
The facility is designed to support multiple clinical and commercial products and includes 16,000sqft of clean room production space. Each of the four clean room suites has independent air handling systems, enabling SurModics to accommodate multiple drug compounds in the same facility. Support utilities and equipment include a 6,000 gallon water-for-injection system, vial washer, autoclave and depyrogenation oven.
The facility is also equipped with the advanced half-suit isolators for aseptic manufacturing processes, which are typically required to handle therapeutic proteins. Support infrastructure includes a 5,300sqft quality control laboratory and a 2,400sqft microbiology laboratory, which will be used to monitor the facility and to test and release products for clinical and commercial use.
The total build out was approximately 90,000sqft and also includes a 4,600sqft engineering lab, which will be used to scale up and develop additional processes.
Bruce Barclay, president and CEO of SurModics, said: "The creation of a world-class current good manufacturing practice facility enhances our capabilities to service our current and future customers from feasibility to commercial sales, and is a critical element in realizing our future growth goals. We continue to be focused on effectively executing our business plan and maintaining our vision of extending and improving the lives of patients through technology innovation."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
For full details on (DNA) DNA. (DNA) has Short Term PowerRatings at TradingMarkets. Details on (DNA) Short Term PowerRatings is available at This Link.
- Research and Markets: Genentech - Company PicShot - 03/19/10
- Rheumatologists Are Eager to Use Roche-Genentech's ACTEMRA, According to New Study by BioTrends - 03/18/10
- Genentech submits sBLA for rheumatoid arthritis drug - 03/18/10
- Genentech Submits Supplemental Biologics License Application for ACTEMRA(R) (tocilizumab) for Prevention of Structural Joint Dam - 03/16/10
- New Board Director Appointed - 03/15/10
- More News >>
